5-Minute Pharma Daily(feeds.transistor.fm)
Merck drops early-stage TROP ADC, keeps deal doors open as Keytruda clock ticksLilly’s weight loss pill reaches brand new patients, even without full-court marketing pressUniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrelBMS positions Cobenfy as safer alternative ahead of pivotal Alzheimer’s psychosis readoutLilly clocks 56% revenue increase in Q1 but declining prices stunt growthPatient death prompts FDA pause on Newron’s Phase 3 schizophrenia studyAstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio
BioPharma Dive - Latest News(biopharmadive.com)
Arvinas’ ‘Protac’ breast cancer drug cleared by FDASummit’s ‘self-inflicted’ stumble; Esperion’s take-private dealModerna sees revenue bump from international COVID vaccine salesBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookTwo biotechs raise a combined $556M in latest spurt of IPOsMerck still sees ‘compelling’ outlook for Terns leukemia drugUniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy
AstraZeneca's £300M UK Investment Resumes Amid FDA Pilot | Pharma and Biotech DailyAstraZeneca's Breztri Asthma Approval Boosts $80B Goal | Pharma and Biotech DailySun Pharma's $11.75B Organon Deal: Industry Shockwave | Pharma and Biotech DailyMerck Unveils PD-1xVEGF Data, Delays Phase 3 Plans | Pharma and Biotech DailyRegeneron Gene Therapy Approved by FDA: A Game-Changer! | Pharma and Biotech DailyAmneal's $1.1B Biosimilars Move & Merck's HIV Pill | Pharma and Biotech DailyMerck Welireg Fails, Roche Enspryng Shines in Trials | Pharma and Biotech Daily
Myomaker Bio unveils lab‑grown human muscle platform to transform drug testingSurvodutide delivers 16.6% weight loss in major phase 3 obesity trialKahimmune Therapeutics signs collaboration agreement with Gustave RoussyBioDuro and CTI Biotechnology form partnership to accelerate preclinical drug developmentAsgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026Theolytics announces first patient dosed in the Octopod‑IP trialUK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention
STAT+: Up and down the ladder: The latest comings and goingsSTAT+: Axsome wins FDA nod for Alzheimer’s agitationSTAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and morePFAS is still in some infant formulaOpinion: America is worrying about fertility again. But it’s not really about familiesOpinion: The psychedelic revolution is leaving behind people of color‘Forever chemicals’ in baby formula? Scientists unpack FDA results